determining algorithm described herein. The following sequences were selected.

I.. N-SQDEVREN-C

II. N-ELSRESREGR-C

III. N-RVLEEEENK-C

IV. N-QKCDSVEE-C

V. N-EETGINRERKVE-C

VI. N-EPEIELPREPRPNEE-C

B. Materials and methods

i. Hep G2 cells were seeded into six-well dishes at 30,0000 cells/well in MEM-supplemented media with 10% FBS. Cells were grown to near confluency and exposed to

I. media alone

II. Mevastatin 5μMol (Cholestrol-lowering Statin drug) and,

III. HMG CoA Reductase peptides at 1, 10 and 100 μMol.

ii. All treatments were carried out in triplicate. After 24 hrs the media was removed and saved.

iii. The cells were washed with 1 ml of PBS and combined with the media. The cells were harvested with 1 ml of 0.1N NaOH.

iv. Samples, both media and cells, were saponified with 0.5 ml 50% KOH, 3 ml ethanol, separately at 80°C for 2 hrs.

v. After cooling, the samples were extracted twice with petroleum ether and washed with NaOH.

vi. The samples were the dried under nitrogen and suspended in 200 μl ethanol.

vii. 50 μl of this suspension was used for determination of cholesterol. Cholesterol was determined in the samples and standards using colorimetric assay (Sigma Kit).

viii. Protein was determined by Lowry's method and the results were expressed as μgm cholesterol/mg protein.

C. Results

i. The following results were obtained:

Peptide	Treatment	Cholesterol Content		Total Cholesterol (μgm/mg protein)	Cholesterol Lowering in % of Control
		Cell	Media		
	Control	152.1 ± 39.0	66.5 ± 6.5	218.6 ± 35.0	-
	Mevastatin 5 μM	124.4 ± 4.4	57.5 ± 5.2	182.0 ± 7.0	18.0
1	1μM	92.5 ± 4.7	65.2 ± 4.0	158.7 ± 5.6	28.0
	10μM	88.6 ± 1.6	60.6 ± 0.5	149.1 ± 2.0	30.0
	100 μM	94.0 ± 4.0	61.1 ± 2.4	155.3 ± 6.4	30.0
2	1μM	94.0 ± 8.3	64.3 ± 4.2	158.3 ± 6.3	29.0
	10μM	85.0 ± 8.4	63.7 ± 9.5	148.6 ± 11.8	33.0
	100 μM	86.0 ± 4.7	59.0 ± 6.0	146.9 ± 8.8	34.0
3	1μM	137.3 ± 4.5	64.0 ± 2.7	201.3 ± 3.3	10.0
	10μM	135.0 ± 4.5	65.5 ± 4.7	200.7 ± 9.0	10.0
	100 μM	135.0 7.0	65.5 ± 1.4	200.5 ± 5.4	10.0

Peptide	Treatment	Cholesterol Content		Total Cholesterol	Cholesterol Lowering in
		Cell	Media	(μgm/mg protein)	% of Control
	Control	151.0± 7.8	50.8 ± 2.5	202.0 ± 5.3	-
	Mevastatin 5μM	125.0 ± 4.6	37.5 ± 3.0	162.6 ± 7.6	19.0
4	1μM	134.7 ± 3.2	50.4 ± 2.5	184.3 ± 5.5	8.0
	10μM	126.1 ± 4.2	49.0 ± 1.0	175.2 ± 3.8	10.0
	100 μM	127.7 ± 9.3	53.8 ± 0.5	181.7 ± 9.3	9.0
5	1μM	140.7 ± 8.6	56.8 ± 1.0	197.0 ± 9.2	1.5
	10μM	149.0 ± 4.4	50.7 ± 1.0	200.0 ± 5.0	0.0
	100 μM	161.7 ± 23.5	48.0 ± 1.6	210.0 ± 25.0	0.0
6	1μM	144.3 ± 7.5	47.4 ± 0.5	192.0 ± 8.0	4.0
	10μM	136.0 ± 12.2	48.0 ± 3.4	184.0 ± 8.4	8.0
	100 μM	132.0 ± 4.4	50.4 ± 1.0	182.4 ± 4.8	9.0

--

REMARKS

Applicant respectfully submits that Example Number 6 does not constitute new matter. Rather, Example Number 6 provides experimental data in support of the presently pending claims.

A Final Office Action relating to the U.S. application serial number 09/232,186 was issued on August 8, 2000. Applicant filed a Notice of Appeal on February 8, 2001, therefore an Appeal Brief was due on April 8, 2001. Applicant hereby requests a THREE-MONTH extension time in lieu of an Appeal Brief; i.e., the filing of this continuation.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.136(a) extension fee to